Why we need pre-registration

There has been a chorus of disapproval this week at the suggestion that researchers should 'pre-register' their studies with journals and spell out in advance the methods and analyses that they plan to do. Those who wish to follow the debate should look at this critique by Sophie Scott, with associated comments, and the responses to it collated here by Pete Etchells. They should also read the explanation of the pre-registration proposals and FAQ  by Chris Chambers - something that many participants in the debate appear not to have done.



Quite simply, pre-registration is designed to tackle two problems in scientific publishing:

• Bias against publication of null results


• A failure to distinguish hypothesis-generating (exploratory) from hypothesis-testing analyses

Either of these alone is bad for science: the combined effect of both of them is catastrophic, and has led to a situation where research is failing to do its job in terms of providing credible answers to scientific questions.

Null results

Let's start with the bias against null results. Much has been written about this, including by me. But the heavy guns in the argument have been wielded by Ben Goldacre, who has pointed out that, in the clinical trials field, if we only see the positive findings, then we get a completely distorted view of what works, and as a result, people may die. In my field of psychology, the stakes are not normally as high, but the fact remains that there can be massive distortion in our perception of evidence.



Pre-registration would fix this by guaranteeing publication of a paper regardless of how the results turn out. In fact, there is another, less bureaucratic, way the null result problem could be fixed, and that would be by having reviewers decide on a paper's publishability solely on the basis of the introduction and methods. But that would not fix the second problem.

Blurring the boundaries between exploratory and hypothesis-testing analyses

A big problem is that nearly all data analysis is presented as if it is hypothesis-testing when in fact much of it is exploratory.



In an exploratory analysis, you take a dataset and look at it flexibly to see what's there. Like many scientists, I love exploratory analyses, because you don't know what you will find, and it can be important and exciting. I suspect it is also something that you get better at as you get more experienced, and more able to see the possibilities in the numbers. But my love of exploratory analyses is coupled with a nervousness. With an exploratory analysis, whatever you find, you can never be sure it wasn't just a chance result. Perhaps I was lucky in having this brought home to me early in my career, when I had an alphabetically ordered list of stroke patients I was planning to study, and I happened to notice that those with names in the first half of the alphabet  had left hemisphere lesions and those with names in the second half had right hemisphere lesions. I even did a chi square test and found it was highly significant. Clearly this was nonsense, and just one of those spurious things that can turn up by chance.



These days it is easy to see how often meaningless 'significant' results occur by running analyses on simulated data - see this blogpost for instance. In my view, all statistics classes should include such exercises.



So you've done your exploratory analysis, got an exciting finding, but are nervous as to whether it is real. What do you do? The answer is you need a confirmatory study. In the field of genetics, failure to realise this led to several years of stasis, cogently described by Flint et al (2010). Genetics really highlights the problem, because of the huge numbers of possible analyses that can be conducted. What was quickly learned was that most exciting effects don't replicate. The bar has accordingly been set much higher, and most genetics journals won't consider publishing a genetic association unless replication has been demonstrated (Munafo & Flint, 2011). This is tough, but it has meant that we can now place confidence in genetics results. (It also has had a positive side-effect of encouraging more collaboration between research groups). Unfortunately, those outside the field of genetics are unaware of these developments, and we are seeing increasing numbers of genetic association studies being published in the neuroscience literature, with tiny samples and no replication.



The important point to grasp is that the meaning of a p-value is completely different if it emerges when testing an a priori prediction, compared with when it is found in the course of conducting numerous analyses of a dataset. Here, for instance, are outputs from 15 runs of a 4-way Anova on random data, as described here:

Each row shows p-value for outputs (main effects then interactions) for one run of 4-way Anova on new set of random data. For a slightly more legible version see here

If I approached a dataset specifically testing the hypothesis that there would be an interaction between group and task, then the chance of a p-value of .05 or less would be 1 in 20  (as can be confirmed by repeating the simulation thousands of times - in a small number of runs it's less easy to see). But if I just looked for significant findings, it's not hard to find something on most of these runs. An exploratory analysis is not without value, but its value is in generating hypotheses that can then be tested in an a priori design.



So replication is needed to deal with the uncertainties around exploratory analysis. How does pre-registration fit in the picture? Quite simply, it makes explicit the distinction between hypothesis-generating (exploratory) and hypothesis-testing research, which is currently completely blurred. As in the example above, if you tell me in advance what hypothesis you are testing, then I can place confidence in the uncorrected statistical probabilities associated with the predicted effects.  If you haven't predicted anything in advance, then I can't.



This doesn't mean that the results from exploratory analyses are necessarily uninteresting, untrue, or unpublishable, but it does mean we should interpret them as what they are: hypothesis-generating rather than hypothesis-testing.



I'm not surprised at the outcry against pre-registration. This is mega. It would require most of us to change our behaviour radically. It would turn on its head the criteria used to evaluate findings: well-conducted replication studies, currently often unpublishable,  would be seen as important, regardless of their results. On the other hand, it would no longer be possible to report exploratory analyses as if they are hypothesis-testing. In my view, unless we do this we will continue to waste time and precious research funding chasing illusory truths.

References

Flint, J., Greenspan, R. J., & Kendler, K. S. (2010). How Genes Influence Behavior: Oxford University press.



Munafo, M, & Flint, J. (2011). Dissecting the genetic architecture of human personality Trends in Cognitive Sciences, 15 (9), 395-400 DOI: 10.1016/j.tics.2011.07.007

Genetic variation and neuroimaging: some ground rules for reporting research

Those who follow me on Twitter may have
noticed signs of tetchiness in my tweets over the past few weeks. In the course
of writing a review article, I’ve been reading papers linking genetic variants
to language-related brain structure and function. This has gone more slowly than I expected for
two reasons. First, the literature gets ever more complicated and technical:
both genetics and brain imaging involve huge amounts of data, and new methods
for crunching the numbers are developed all the time. If you really want to understand
a paper, rather than just assuming the Abstract is accurate, it can be a long,
hard slog, especially if, like me, you are neither a geneticist nor a
neuroimager. That’s understandable and perhaps unavoidable. The other reason,
though, is less acceptable. For all their complicated methods, many of the
papers in this area fail to tell the reader some important and quite basic
information. This is where the tetchiness comes in. Having burned my brains out
trying to understand what was done, I then realise that I have no idea about
something quite basic like the sample size. The initial assumption is that I’ve
missed it, and so I wade through the paper again, and the Supplementary Material, looking
for the key information. Only when I’m absolutely certain that it’s not there,
am I reduced to writing to the authors for the information. So
this is a plea – to authors, editors and reviewers. If a paper is concerned
with an association between a genetic variant and a phenotype (in my case the
interest is in neural phenotypes, but I suspect this applies more widely) then
could we please ensure that the following information is clearly reported in
the Methods or Results section

1. What genetic variant are we talking about?
You might think this is very simple, but it’s not: for instance, one of the
genes I’m interested in is CNTNAP2, which has been associated with a range of
neurodevelopmental disorders, especially those affecting language. The evidence
for a link between CNTNAP2 and developmental disorders comes from studies that
have examined variation in single-nucleotide polymorphisms or SNPs. These are
segments of DNA that are useful in revealing differences between people because
they are highly variable. DNA is composed of four bases, C, T, G, and A in
paired strands. So for instance, we might have a locus where some people have
two copies of C, some have two copies of T, and others have a C and a T. SNPs
are not  necessarily a functional part of
the gene itself – they may be in a non-coding region, or so close to a gene that
variation in the SNP co-occurs with variation in the gene. Many different SNPs
can index the same gene. So for CNTNAP2, Vernes et al (2008)tested 38 SNPs,
ten of which were linked to language problems. So we have to decide which SNP
to study – or whether to study all of them. And we have to decide how to do the
analysis. For instance, SNP rs2710102 can take the form CC, CT or TT. We could
look for a dose response effect (CC < CT < TT) or we could compare CC/CT with TT, or we could compare CC with CT/TT. Which of these we do may depend on whether prior research suggests the genetic effect is additive or dominant, but for brain imaging studies grouping can also be dictated by practical considerations: it’s usual to compare just two groups and to combine genotypes to give a reasonable sample size. If you’ve followed me so far, and you have some background in statistics, you will already be starting to see why this is potentially problematic. If the researcher can select from ten possible SNPs, and two possible analyses, the opportunities for finding spuriously ‘significant’ results are increased. If there are no directional predictions – i.e. we are just looking for a difference between two groups, but don’t have a clear idea of what type of difference will be associated with ‘risk’ – then the number of potentially ‘interesting’ results is doubled.

For CNTNAP2, I found two papers that had
looked at brain correlates of SNP rs2710102. Whalley et al (2011) found that adults
with the CC genotype had different patterns of brain activation from CT/TT
individuals. However, the other study, by Scott-van Zeeland et al (2010), treated
CC/CT as a risk genotype that was compared with TT. (This was not clear in the
paper, but the authors confirmed it was what they did).

 Four studies looked at another SNP -
rs7794745, on the basis that an increased risk of autism had been reported for
the T allele in males. Two of them (Tan et al, 2010; Whalley et al, 2010) compared TT vs TA/AA and two (Folia et al, 2011; Kos et al, 2012) compared
TT/TA with AA. In any case, the ground is rather cut from under the feet of
these researchers by a recent failure to replicate an association of this SNP
with autism (Anney et al, 2012).

2. Who are the participants? It’s not very
informative to just say you studied “healthy volunteers”. There are some types
of study where it doesn’t much matter how you recruited people. A study looking
at genetic correlates of cognitive ability isn’t one of them. Samples of
university students, for instance, are not representative of the general
population, and aren’t likely to include many people with significant language
problems.

3. How many people in the study had each type
of genetic variant? And if subgroup analyses are reported, how many people in
each subgroup had each type of genetic variant? I've found that papers in top-notch journals often fail to provide this basic
information.

Why is this important? For a start, likelihood
of showing significant activation of a brain region will be affected by sample
size. Suppose you have 24 people with genotype A and 8 with genotype B. You
find significant activation of brain region X in those with genotype A, but not
for those with genotype B. If you don’t do an explicit statistical comparison
of groups (you should - but many people don’t) you may be misled into concluding that brain
activation is defective in genotype B – when in fact you just have low power to
detect effects in that group because it is so small.

In addition, if you don’t report the N, then
it’s difficult to get an idea of the effect size and confidence interval for
any effect that is reported. The reasons why this is optimal are
well-articulated here. This issue has been much discussed in psychology, but seems not to have
permeated the field of genetics, where reliance on p-values seems the norm. In
neuroimaging it gets particularly complicated, because some form of correction
for ‘false discovery’ will be applied when multiple comparisons are conducted. It’s
often hard to work out quite how this was done, and you can end up staring at
a table that shows brain regions and p-values, with only a vague idea of how
big a difference there actually is between groups.

 Most of the SNPs that are being used in brain studies are ones that
were found to be associated with a behavioural phenotype in large-scale genomic
studies where the sample size would include hundreds if not thousands of
individuals, so small effects could be detected. Brain-based studies often use
sample sizes that are relatively small, but some of them find large, sometimes
very large, effects. So what does that mean? The optimistic interpretation is
that a brain-based phenotype is much closer to the gene effect, and so gives
clearer findings. This is essentially 
the argument used by those who talk of ‘endophenotypes’ or ‘biomarkers’.
There is, however, an alternative, and much more pessimistic view, which is
that studies linking genotypes with brain measures are prone to generate false
positive findings, because there are too many places in the analysis pipeline
where the researchers have opportunities to pick and choose the analysis that
brings out the effect of interest most clearly. Neuroskeptic has a nice blogpost illustrating this well-known problem in
the neuroimaging area; matters are only made worse by uncertainty re SNP classification
(point 1).

A source of concern here is the
unpublishability of null findings. Suppose you did a study where you looked at,
say, 40 SNPs and a range of measures of brain structure, covering the whole
brain. After doing appropriate corrections for multiple comparisons, nothing is
significant. The sad fact is that your study is unlikely to find a home in a
journal. But is this right? After all, we don’t want to clutter up the
literature with a load of negative results. The answer depends on your sample
size, among other things. In a small sample, a null result might well reflect
lack of statistical power to detect a small effect. This is precisely why
people should avoid doing small studies: if you find nothing, it’s
uninterpretable. What we need are studies that allow us to say with confidence
whether or not there is a significant gene effect.

4. How do the genetic/neuroimaging results relate to cognitive measures in your sample?  Your notion that ‘underactivation of brain area
X’ is an endophenotype that leads to poor language, for instance, doesn’t look
very plausible if people who have such underactivation have excellent language skills. Out
of five papers on CNTNAP2 that I reviewed, three made no mention of cognitive measures,
one gathered cognitive data but did not report how it related to genotype or
brain measures, and only one provided some relevant, though sketchy, data.

5. Report negative findings. The other kind of
email I’ve been writing to people is one that says – could you please clarify
whether your failure to report on the relationship between X and Y was because
you didn’t do that analysis, or whether you did the analysis but failed to find
anything. This is going to be an uphill battle, because editors and reviewers
often advise authors to remove analyses with nonsignificant findings. This is a
very bad idea as it distorts the literature.

And last of all....

A final plea is not so much to journal
editors as to press officers. Please be aware that studies of common SNPs aren't the same as studies of rare genetic mutations. The genetic variants in the
studies I looked at were all relatively common in the general population, and so
aren't going to be associated with major brain abnormalities. Sensationalised
press releases can only cause confusion:

This release on the Scott van-Zeeland (2010) study described neuroimaging
findings from  CNTNAP2 variants that are found in over 70% of the population. It claims that: 

• “A gene variant tied to autism rewires the
  brain"

• "Now we can begin to unravel the mystery
  of how genes rearrange the brain's circuitry, not only in autism but in many
  related neurological disorders."

• “Regardless of their diagnosis, the children
  carrying the risk variant showed a disjointed brain. The frontal lobe was
  over-connected to itself and poorly connected to the rest of the brain”

• "If we determine that the CNTNAP2
  variant is a consistent predictor of language difficulties, we could begin to
  design targeted therapies to help rebalance the brain and move it toward a path
  of more normal development."

Only at the end of the press release, are we
told that "One third of the population [sic: should be two thirds] carries this variant in its DNA.
It's important to remember that the gene variant alone doesn't cause autism, it
just increases risk." 

References

Anney, R., Klei, L.,
Pinto, D., Almeida, J., Bacchelli, E., Baird, G., . . . Devlin, B. .
Individual common variants exert weak effects on the risk for autism spectrum
disorders. Human Molecular Genetics, 21(21), 4781-4792. doi: 10.1093/hmg/dds301(2012)

V. Folia, C. Forkstam, M.
Ingvar, P. Hagoort, K. M. Petersson, Implicit artificial syntax processing:
Genes, preference, and bounded recursion. Biolinguistics 5,  (2011).

M. Kos et al., CNTNAP2
and language processing in healthy individuals as measured with ERPs. PLOS One
7,  (2012).

Scott-Van Zeeland, A., Abrahams, B., Alvarez-Retuerto, A., Sonnenblick, L., Rudie, J., Ghahremani, D., Mumford, J., Poldrack, R., Dapretto, M., Geschwind, D., & Bookheimer, S. (2010). Altered Functional Connectivity in Frontal Lobe Circuits Is Associated with Variation in the Autism Risk Gene CNTNAP2 Science Translational Medicine, 2 (56), 56-56 DOI: 10.1126/scitranslmed.3001344

G. C. Tan, T. F. Doke, J.
Ashburner, N. W. Wood, R. S. Frackowiak, Normal variation in fronto-occipital
circuitry and cerebellar structure with an autism-associated polymorphism of
CNTNAP2. Neuroimage 53, 1030 (2010).

Vernes, S. C., Newbury,
D. F., Abrahams, B., Winchester, L., Nicod, J., Groszer, M., . . . Fisher, S.  A functional genetic link between distinct developmental language
disorders. New England Journal of Medicine, 359, 2337-2345. (2008).

H. C. Whalley et al.,
Genetic variation in CNTNAP2 alters brain function during linguistic processing
in healthy individuals. Am. J. Med. Genet. B 156B, 941 (2011).